Retrospective Analyses of Complete Resection Combined with Systemic Chemotherapy and Targeted Therapy for Patients with Ovarian Metastases from Colorectal Cancer

2021 ◽  
Author(s):  
Gangling Tong ◽  
Qianjiang Luo ◽  
Xionghao Pang ◽  
Boran Chen ◽  
Guoqing Lv ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapy ◽  
Systemic Chemotherapy ◽  
Complete Resection ◽  
Ovarian Metastases

scholarly journals Impact of ovarian metastatectomy on survival outcome of colorectal cancer patients with ovarian metastasis: a retrospective study

2020 ◽  
Author(s):  
Xiaofen Li ◽  
Hai Huang ◽  
Longyao Ran ◽  
Chao Fang ◽  
Yongyang Yu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Primary Tumor ◽  
Systemic Chemotherapy ◽  
Ovarian Metastasis ◽  
Complete Resection ◽  
Survival Outcome ◽  
Palliative Resection ◽  
Ovarian Metastases ◽  
The Impact

Abstract Background Ovarian metastasis from colorectal cancer (CRC) is rare and lacks standard treatment. The benefit of metastatectomy remains to be elucidated. This study was conducted to assess the impact of metastatectomy on survival outcome and explore prognostic factors in ovarian metastatic CRC patients. Results Information of ovarian metastatic CRC patients between January 2008 and December 2017 were collected retrospectively from database of West China Hospital, Sichuan University. Totally, 68 female patients from a cohort of 2170 metastatic CRC cases were eligible. The median age at diagnosis was 46.5 years old. The median DSS was 25.0 months (95% confidence interval (CI): 21.0-29.0 months). Kaplan-Meier analysis and log-rank test showed that complete resection of ovarian metastases (median DSS: 33.0 months) could significantly prolong patients’ survival time, comparing with palliative and no resection (median DSS: 20.0 months and 22.0 months, respectively), regardless of systemic chemotherapy (P<0.05). Multivariate analysis demonstrated regional lymph nodes metastasis of primary tumor (hazard ratio (HR): 3.438, 95%CI: 1.094-10.810, P=0.035), primary tumor resection (HR: 6.436, 95%CI: 1.770-23.399, P=0.005), differentiation grade (HR: 0.272, 95%CI: 0.107-0.693, P=0.006), complete resection of ovarian metastases (versus palliative resection: HR: 17.091, 95%CI: 3.040-96.099, P=0.001; versus no resection: HR: 9.519, 95%CI: 1.581-57.320, P=0.014), and systemic chemotherapy (HR: 3.059, 95%CI: 1.089-8.595 P=0.034) were independent prognostic factors. Conclusions Complete resection of ovarian metastases could independently predict favorable survival in ovarian metastatic CRC, while palliative resection could not improve patients’ prognosis compared with no resection.

Retrospective analysis of the effects of systemic chemotherapy to the ovarian metastases from colorectal cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 731-731 ◽  
Author(s):  
Katsutoshi Sekine ◽  
Tetsuya Hamaguchi ◽  
Hirokazu Shoji ◽  
Shoko Nakamura ◽  
Takahiro Miyamoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Surgical Resection ◽  
Cytoreductive Surgery ◽  
Systemic Chemotherapy ◽  
Palliative Chemotherapy ◽  
Objective Response ◽  
First Line ◽  
Ovarian Metastases ◽  
Third Line ◽  
Metastatic Sites

731 Background: Ovarian metastases from colorectal cancers are relatively rare. Since most ovarian metastases are also associated with other metastatic sites, the prognosis is reported to be poor. It is not fully understood whether the response to systemic chemotherapy of ovarian metastases differs from that to other metastatic sites. Methods: We retrospectively reviewed the clinical data of patients with ovarian metastases from colorectal cancer treated at our hospital between January 2006 and December 2015. Results: Among the 635 female patients with relapsed or metastatic colorectal cancer, 57 (9.0%) had ovarian metastases before the first-line treatment; 37 patients received palliative chemotherapy, and 20 patients were initially treated by surgical resection. In addition, 38 cases of ovarian metastases developed after the initiation of first-line chemotherapy. Overall, 95 patients (15.0%) with ovarian metastases were treated during this period. The objective response rate for systemic chemotherapy of ovarian metastases was lower than that for other metastatic sites (22.9 % vs 60.9 % for first-line, 3.4 % vs 13.6 % for second-line, 11.1 % vs 26.6 % for third-line, and 0% vs 18.2 % for fourth-line, respectively). After the initiation of chemotherapy, surgical resection of ovarian metastases was positively associated with a longer overall survival (26.8 months for cytoreductive surgery and 17.0 months for only systemic chemotherapy, p < 0.001), especially when the other metastatic sites had not progressed after chemotherapy. Conclusions: Ovarian metastases are less responsive to systemic chemotherapy compared to the extra-ovarian metastases. Our data also suggest that multi-disciplinary treatment strategy including systemic chemotherapy and cytoreductive surgery might improve the prognosis of ovarian metastases.

Complete resection of colorectal cancer with ovarian metastases combined with chemotherapy is associated with improved survival

2018 ◽  
Vol 89 (9) ◽  
pp. 1091-1096 ◽  
Author(s):  
Ibrahim S. Al‐Busaidi ◽  
Teresa Bailey ◽  
Bruce Dobbs ◽  
Tim W. Eglinton ◽  
Christopher J. Wakeman ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Complete Resection ◽  
Ovarian Metastases

scholarly journals Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4590
Author(s):  
Hee Yeon Lee ◽  
In Sook Woo
Keyword(s):  
Colorectal Cancer ◽  
Systemic Chemotherapy ◽  
Systemic Treatment ◽  
Complete Resection ◽  
New Drugs ◽  
Term Survival ◽  
Free Survival ◽  
Resectable Cancer ◽  
Overall Survival Benefit

The liver is the most common site of metastases for colorectal cancer. Complete resection in some patients with resectable liver metastases (LM) can lead to long-term survival and cure. Adjuvant systemic chemotherapy after complete resection of LM improves recurrence-free survival; however, the overall survival benefit is not clear. In selected patients, preoperative systemic treatment for metastatic colorectal cancer can convert unresectable to resectable cancer. This review will focus on patient selection, and integration of perioperative and postoperative systemic treatment to surgery in resectable and initially unresectable LM. Additionally, new drugs and biomarkers will be discussed.

scholarly journals Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision

2020 ◽  
Vol 54 (3) ◽  
pp. 272-277
Author(s):  
Martina Rebersek
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapy ◽  
Systemic Chemotherapy ◽  
Systemic Treatment ◽  
Molecular Subtypes ◽  
Signalling Pathways ◽  
Specific Patient ◽  
Medical Oncologists ◽  
New Knowledge ◽  
The World

AbstractBackgroundColorectal cancer (CRC) is one of the most common types of cancer in the world. Metastatic disease is still incurable in most of these patients, but the survival rate has improved by treatment with novel systemic chemotherapy and targeted therapy in combination with surgery. New knowledge of its complex heterogeneity in terms of genetics, epigenetics, transcriptomics and microenvironment, including prognostic and clinical characteristics, led to its classification into various molecular subtypes of metastatic CRC, called consensus molecular subtypes (CMS). The CMS classification thus enables the medical oncologists to adjust the treatment from case to case. They can determine which type of systemic chemotherapy or targeted therapy is best suited to a specific patient, what dosages are needed and in what order.ConclusionsCMS in metastatic CRC are the new tool to include the knowledge of molecular factors, tumour stroma and signalling pathways for personalized, patient-orientated systemic treatment in precision medicine.

Retrospective Analyses of Systemic Chemotherapy and Cytoreductive Surgery for Patients with Ovarian Metastases from Colorectal Cancer: A Single-Center Experience

Oncology ◽  
2018 ◽  
Vol 95 (4) ◽  
pp. 220-228 ◽  
Author(s):  
Katsutoshi Sekine ◽  
Tetsuya Hamaguchi ◽  
Hirokazu Shoji ◽  
Atsuo Takashima ◽  
Yoshitaka Honma ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cytoreductive Surgery ◽  
Systemic Chemotherapy ◽  
Single Center ◽  
Ovarian Metastases ◽  
Single Center Experience

scholarly journals Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer

2021 ◽  
Vol 22 (4) ◽  
pp. 2067
Author(s):  
Rhynelle S. Dmello ◽  
Sarah Q. To ◽  
Ashwini L. Chand
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapy ◽  
Liver Metastasis ◽  
Metastatic Colorectal Cancer ◽  
Tumour Microenvironment ◽  
Tumour Cells ◽  
Cellular Interactions ◽  
Circulating Tumour Cells ◽  
Therapeutic Targeting ◽  
Colorectal Cancer Patients

Liver metastasis is the primary contributor to the death of patients with colorectal cancer. Despite the overall success of current treatments including targeted therapy, chemotherapy, and immunotherapy combinations in colorectal cancer patients, the prognosis of patients with liver metastasis remains poor. Recent studies have highlighted the importance of the tumour microenvironment and the crosstalk within that determines the fate of circulating tumour cells in distant organs. Understanding the interactions between liver resident cells and tumour cells colonising the liver opens new therapeutic windows for the successful treatment of metastatic colorectal cancer. Here we discuss critical cellular interactions within the tumour microenvironment in primary tumours and in liver metastases that highlight potential therapeutic targets. We also discuss recent therapeutic advances for the treatment of metastatic colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document